John Christopher Kunich

US Patent:

20100099123, Apr 22, 2010

Filed:

Dec 21, 2006

Appl. No.:

12/158877

Inventors:

Cheng Liu - Richmond CA, US
John Kunich - Emeryville CA, US
Michael Kavanaugh - Emeryville CA, US

Assignee:

Novartis AG - Basel
Xoma Technology Ltd. - Hamilton

International Classification:

G01N 33/53

US Classification:

435 792

Abstract:

Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.

US Patent:

20140030738, Jan 30, 2014

Filed:

Feb 20, 2013

Appl. No.:

13/771395

Inventors:

- Basel, CH
John Kunich - Orinda CA, US
William Michael Kavanaugh - Orinda CA, US

Assignee:

XOMA TECHNOLOGY LTD. - Berkeley CA
NOVARTIS AG - Basel

International Classification:

G01N 33/68

US Classification:

435 772, 435 792

Abstract:

Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.

US Patent:

20090155821, Jun 18, 2009

Filed:

Jan 4, 2007

Appl. No.:

12/159827

Inventors:

John Kunich - San Leandro CA, US
Cheng Liu - Richmond CA, US

International Classification:

G01N 33/574
G01N 33/566

US Classification:

435 723, 435 72

Abstract:

Methods for detecting antibody dependent cellular cytotoxicity (ADCC) are described herein. The methods are label-free, and can be performed in real time on adherent cells. The methods can include, for example, (a) monitoring the impedance between electrodes on a non-conducting substrate that supports the growth of target cells in an assay medium; and (b) adding effector cells and an antibody that binds to the target cells to the assay medium; wherein any decrease in the impedance between the electrodes on the substrate following addition of the effector cells and the antibody is indicative of ADCC function having been effected in the assay medium.